Print E-mail
Volume 45, Number 1, February 2012

Role of moxifloxacin for the treatment of community-acquired complicated intra-abdominal infections in Taiwan

Yeu-Jun Lau, Yen-Hsu Chen, Ching-Tai Huang, Wen-Sen Lee, Cheng-Yi Liu, Jien-Wei Liu, Hsiao-Dong Liu, Yuarn-Jang Lee, Chao-Wen Chen, Wen-Chien Ko, Po-Ren Hsueh

Received: October 24, 2011    Revised: November 3, 2011    Accepted: January 13, 2012   


Corresponding author:

Po-Ren Hsueh, Departments of Laboratory Medicine and Internal Medicine, National Taiwan University College of Medicine, 7 Chung Shan South Road, Taipei 100, Taiwan.


Background and purpose: 

Complicated intra-abdominal infections (cIAIs) are common yet serious infections that can potentially lead to substantial morbidity and morbidity. As an essential adjunct to source control, the goals of antimicrobial therapy are to promote patient recovery, reduce recurrence risk, and prevent antimicrobial resistance. The current international guidelines on the empirical treatment of community-acquired complicated IAIs were published by the Infectious Diseases Society of America (IDSA) and Surgical Infections Society (SIS) in 2010. These guidelines all recommend the use of a fluoroquinolone (ciprofloxacin or levofloxacin) plus metronidazole for mild-to-moderate- and high-severity cases. Moxifloxacin monotherapy is recommended by the current IDSA/SIS guidelines for the treatment of mild-to-moderate complicated IAIs. Moxifloxacin has demonstrated a broad spectrum coverage of both aerobic and anaerobic pathogens, good tissue penetration into the gastrointestinal tract, and a good tolerability profile. Clinical data have demonstrated that moxifloxacin is at least as effective as other standard therapeutic regimens recommended by current clinical guidelines. Due to the high rates of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and fluoroquinolone-resistant Enterobacteriaceae among isolates causing community-acquired IAIs in Asia, any fluoroquinolones (including moxifloxacin) are not recommended as drugs of choice for the empirical treatment of community-acquired IAIs, particularly in countries (China, India, Thailand, and Vietnam) with fluoroquinolone resistance rates among Escherichia coli isolates of >20%. Given the low rates of fluoroquinolone-resistant (<20%) and extended-spectrum β-lactamase (ESBL)-producing (<10%) Enterobacteriaceae isolates associated community-acquired IAIs in Taiwan, it appears that moxifloxacin is considered an appropriate first-line therapy for patients with community-acquired complicated IAIs in this country.


Key words:

Antimicrobial therapy, Complicated intra-abdominal infections, Fluoroquinolones, Moxifloxacin